Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 13/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629969 | 0.90 | TERT (1.00) | TERTMAPTALDH1A1TP53L3MBTL1 | |
| SCHEMBL4298492 | 0.89 | TERT (1.00) | TERTMAPTALDH1A1 | |
| SCHEMBL8704683 | 0.89 | TERT (1.00) | TERTMAPTALDH1A1 | |
| SCHEMBL8706042 | 0.88 | TERT (1.00) | TERTMAPTALDH1A1 | |
| SCHEMBL4289287 | 0.88 | TERT (0.74) | TERTMAPTALDH1A1LMNA | |
| SCHEMBL4300594 | 0.88 | TERT (1.00) | TERTMAPTALDH1A1 | |
| SCHEMBL9630688 | 0.88 | TERT (0.74) | TERTMAPTALDH1A1LMNA | |
| SCHEMBL3115635 | 0.88 | TERT (1.00) | TERTMAPTALDH1A1 | |
| SCHEMBL8706439 | 0.88 | TERT (1.00) | TERTMAPTALDH1A1 | |
| SCHEMBL9630665 | 0.86 | TERT (0.79) | TERTMAPTALDH1A1LMNACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | TERT, NAT10, POT1 | TERT 1/4885MAPT 4711/4885ALDH1A1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.